We are live on ! Find out more
NBIX icon

Neurocrine Biosciences
NBIX

302 hedge funds and large institutions have $7.51B invested in Neurocrine Biosciences in 2019 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 119 increasing their positions, 103 reducing their positions, and 53 closing their positions.

New
Increased
Maintained
Reduced
Closed

52% more call options, than puts

Call options by funds: $73.7M | Put options by funds: $48.6M

16% more repeat investments, than reductions

Existing positions increased: 119 | Existing positions reduced: 103

14% more funds holding in top 10

Funds holding in top 10: 7 → 8 (+1)

0% more ownership

Funds ownership: 97.45% → 97.45% (+0%)

4% less capital invested

Capital invested by funds: $7.8B → $7.51B (-$289M)

7% less funds holding

Funds holding: 325 → 302 (-23)

30% less first-time investments, than exits

New positions opened: 37 | Existing positions closed: 53

Holders
302
Holders Change
-23
Holders Change %
-7.08%
% of All Funds
6.56%
Holding in Top 10
8
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+14.29%
% of All Funds
0.17%
New
37
Increased
119
Reduced
103
Closed
53
Calls
$73.7M
Puts
$48.6M
Net Calls
+$25.1M
Net Calls Change
-$5.84M

Top Buyers

1
BG
Bellevue Group
Switzerland
+$290M
2
Capital International Investors
Capital International Investors
California
+$98.8M
3
HM
HealthCor Management
New York
+$70.2M
4
N
Nuveen
North Carolina
+$63M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
+$60.4M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$101M
2
Invesco
Invesco
Georgia
-$52.9M
3
MWNA
Marshall Wace North America
New York
-$51.2M
4
JP Morgan Chase
JP Morgan Chase
New York
-$49.4M
5
Marshall Wace
Marshall Wace
United Kingdom
-$33M
Name Holding Trade Value Shares
Change 		Change in
Stake
Janus Henderson Group
1
Janus Henderson Group
United Kingdom
$790M +$44.4M +540,279 +6%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$777M -$101M -1,231,257 -12%
Vanguard Group
3
Vanguard Group
Pennsylvania
$685M -$3.16M -38,488 -0.5%
BlackRock
4
BlackRock
New York
$478M +$13.4M +163,195 +3%
Capital International Investors
5
Capital International Investors
California
$475M +$98.8M +1,203,754 +27%
PA
6
Perceptive Advisors
New York
$340M +$21.8M +265,200 +7%
BG
7
Bellevue Group
Switzerland
$299M +$290M +3,526,244 +17,457%
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
$286M -$7.75M -94,381 -3%
HM
9
HealthCor Management
New York
$200M +$70.2M +855,300 +56%
State Street
10
State Street
Massachusetts
$157M -$13.4M -162,723 -8%
O
11
OrbiMed
New York
$155M – – –
Franklin Resources
12
Franklin Resources
California
$139M -$31.8M -387,307 -19%
BBA
13
Baker Bros. Advisors
New York
$119M +$26M +316,613 +29%
Invesco
14
Invesco
Georgia
$108M -$52.9M -644,606 -34%
First Trust Advisors
15
First Trust Advisors
Illinois
$108M +$16M +194,643 +18%
AllianceBernstein
16
AllianceBernstein
Tennessee
$102M +$8.12M +98,945 +9%
Point72 Asset Management
17
Point72 Asset Management
Connecticut
$95M +$60.4M +735,992 +189%
RSCM
18
Rock Springs Capital Management
Maryland
$86.4M +$14.7M +178,500 +21%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$82.4M +$2.23M +27,195 +3%
Bank of New York Mellon
20
Bank of New York Mellon
New York
$80.5M -$142K -1,728 -0.2%
PAMU
21
Pictet Asset Management (UK)
United Kingdom
$80.2M -$2.42M -29,518 -3%
Deutsche Bank
22
Deutsche Bank
Germany
$76.3M -$9.89M -120,494 -12%
Norges Bank
23
Norges Bank
Norway
$72.3M – – –
Two Sigma Advisers
24
Two Sigma Advisers
New York
$67.5M +$3.48M +42,400 +6%
N
25
Nuveen
North Carolina
$64.7M +$63M +766,778 New
1
2 3 4 5

NBIX Hedge Fund Activity: Q2 2019 in Review

302 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q2 2019, worth a combined $7.51B — down 3.7% from $7.8B a quarter earlier.

Sellers outnumbered buyers: 53 funds closed out of NBIX and 37 opened new positions — a net loss of 16 holders — while 103 trimmed existing stakes and 119 added.

The largest buyer was Bellevue Group, adding an estimated $290M. The largest seller was Fidelity Investments, cutting an estimated $101M.

  • 302 institutional investors held Neurocrine Biosciences (NBIX) as of Q2 2019, down from 325 in Q1 2019.
  • Funds reported $7.51B of Neurocrine Biosciences stock for Q2 2019, down 3.7% quarter-over-quarter.
  • 37 funds opened new Neurocrine Biosciences positions in Q2 2019 and 53 closed out, a net change of -16 holders.
  • The largest Neurocrine Biosciences buyer in Q2 2019 was Bellevue Group, an estimated $290M added.
  • The largest Neurocrine Biosciences seller in Q2 2019 was Fidelity Investments, an estimated $101M sold.

Based on aggregated 13F filings for Q2 2019.